Pulmonary aspergillosis and mucormycosis in a patient with COVID-19

Andre K Johnson; Zeron Ghazarian; Kristina D Cendrowski; Jon G Persichino

doi:10.1016/j.mmcr.2021.03.006

Pulmonary aspergillosis and mucormycosis in a patient with COVID-19

Med Mycol Case Rep. 2021 Jun:32:64-67. doi: 10.1016/j.mmcr.2021.03.006. Epub 2021 Apr 7.

Authors

Andre K Johnson¹, Zeron Ghazarian², Kristina D Cendrowski³, Jon G Persichino¹

Affiliations

¹ Riverside Community Hospital, Division of Infectious Diseases, 4445 Magnolia Avenue, Riverside, CA, 92501, USA.
² Riverside Community Hospital, Division of Pulmonary and Critical Care, 4445 Magnolia Avenue, Riverside, CA, 92501, USA.
³ Riverside Community Hospital, Department of Pathology, 4445 Magnolia Avenue, Riverside, CA, 92501, USA.

Abstract

Invasive pulmonary mucormycosis and aspergillosis are rare, life-threatening fungal infections. Most documented cases have been reported in patients with diabetes mellitus, neutropenia, or treatment with corticosteroids. Both infections have been recognized as secondary complications of COVID-19, especially among critically ill patients. We report the first case of combined probable pulmonary aspergillosis and possible mucormycosis in a male with COVID-19 in the ICU.

Keywords: Aspergillosis; COVID-19; Invasive; Mucormycosis; Pulmonary.

Publication types

Case Reports